TOI Earnings

TOI reported its earnings on 2026-03-19, showcasing a revenue of against an estimate of 141.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.08 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following TOI's earnings announcement on 2026-03-19, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, TOI's stock price tends to shift by an average of 6.22% in the 10 days leading up to earnings and -14.76% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate TOI's annual revenue to reach 139.78M, while the EPS is projected at -0.09. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between TOI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, TOI's stock price typically moves by 6.22% in the 10 days before its earnings and -14.76% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.09 and revenue of 139.78M.

The earnings call summary and Q&A session indicate positive sentiment: strong revenue growth expectations, improved gross margins, sustainable profitability, and positive free cash flow by Q4 2025. The pharmacy business is expanding, and new contracts are expected to boost growth. Despite some unclear responses, the overall outlook is optimistic, with AI initiatives and strategic expansions. The positive impact of external changes like lower drug costs further supports this view. However, the negative cash flow and reserve adjustments are minor concerns, leading to a positive, but not strong positive, sentiment.